 [1m([0morchestrator-bleeding-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ENALAPRIL MALEATE increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-ENALAPRIL MALEATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ENALAPRIL MALEATE increase or decrease the risk of bleeding?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-ENALAPRIL MALEATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ENALAPRIL MALEATE increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-ENALAPRIL MALEATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ENALAPRIL MALEATE increase or decrease the risk of bleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ENALAPRIL MALEATE increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ENALAPRIL MALEATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ENALAPRIL MALEATE: adverse_reactions: In patients treated with enalapril maleate, the maximum duration of therapy was three years; in placebo-treated patients the maximum duration of therapy [0m
[31mwas [0m[1;31m12[0m[31m weeks. Enalapril Maleate [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m2314[0m[1;31m)[0m[31m Incidence [0m[1;31m([0m[31mdiscontinuation[0m[1;31m)[0m[31m Placebo [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m230[0m[1;31m)[0m[31m Incidence Body As A Whole Fatigue [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m<[0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m2.6[0m[31m Orthostatic Effects [0m[1;31m1.2[0m[31m [0m[1;31m([0m[31m<[0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m Asthenia [0m[1;31m1.1[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0.9[0m[31m Digestive [0m
[31mDiarrhea [0m[1;31m1.4[0m[31m [0m[1;31m([0m[31m<[0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m1.7[0m[31m Nausea [0m[1;31m1.4[0m[31m [0m[1;31m([0m[1;31m0.2[0m[1;31m)[0m[31m [0m[1;31m1.7[0m[31m Nervous/Psychiatric Headache [0m[1;31m5.2[0m[31m [0m[1;31m([0m[1;31m0.3[0m[1;31m)[0m[31m [0m[1;31m9.1[0m[31m Dizziness [0m[1;31m4.3[0m[31m [0m[1;31m([0m[1;31m0.4[0m[1;31m)[0m[31m [0m[1;31m4.3[0m[31m Respiratory Cough [0m[1;31m1.3[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m. ENALAPRIL MALEATE: adverse_reactions: [0m[1;31m9[0m[31m Skin Rash [0m[1;31m1.4[0m[31m [0m
[1;31m([0m[1;31m0.4[0m[1;31m)[0m[31m [0m[1;31m0.4[0m[31m Heart Failure Adverse experiences occurring in greater than one percent of patients with heart failure treated with enalapril maleate are shown below. The incidences represent the [0m
[31mexperiences from both controlled and uncontrolled clinical trials [0m[1;31m([0m[31mmaximum duration of therapy was approximately one year[0m[1;31m)[0m[31m. In the placebo-treated patients, the incidences reported are from the [0m
[31mcontrolled trials [0m[1;31m([0m[31mmaximum duration of therapy is [0m[1;31m12[0m[31m weeks[0m[1;31m)[0m[31m. The percentage of patients with severe heart failure [0m[1;31m([0m[31mNYHA Class IV[0m[1;31m)[0m[31m was [0m[1;31m29[0m[31m percent and [0m[1;31m43[0m[31m percent for patients treated with enalapril [0m
[31mmaleate and placebo, respectively. Enalapril Maleate [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m673[0m[1;31m)[0m[31m Incidence [0m[1;31m([0m[31mdiscontinuation[0m[1;31m)[0m[31m Placebo [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m339[0m[1;31m)[0m[31m Incidence Body As A Whole Orthostatic Effects [0m[1;31m2.2[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0.3[0m[31m Syncope [0m[1;31m2.2[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0.9[0m[31m Chest Pain [0m[1;31m2[0m[31m.[0m
[31mENALAPRIL MALEATE: adverse_reactions: [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m [0m[1;31m2.1[0m[31m Fatigue [0m[1;31m1.8[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m [0m[1;31m1.8[0m[31m Abdominal Pain [0m[1;31m1.6[0m[31m [0m[1;31m([0m[1;31m0.4[0m[1;31m)[0m[31m [0m[1;31m2.1[0m[31m Asthenia [0m[1;31m1.6[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0.3[0m[31m Cardiovascular Hypotension [0m[1;31m6.7[0m[31m [0m[1;31m([0m[1;31m1.9[0m[1;31m)[0m[31m [0m[1;31m0.6[0m[31m Orthostatic Hypotension [0m[1;31m1.6[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0.3[0m[31m [0m
[31mAngina Pectoris [0m[1;31m1.5[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m1.8[0m[31m Myocardial Infarction [0m[1;31m1.2[0m[31m [0m[1;31m([0m[1;31m0.3[0m[1;31m)[0m[31m [0m[1;31m1.8[0m[31m Digestive Diarrhea [0m[1;31m2.1[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m1.2[0m[31m Nausea [0m[1;31m1.3[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0.6[0m[31m Vomiting [0m[1;31m1.3[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m [0m[1;31m0.9[0m[31m Nervous/Psychiatric Dizziness [0m[1;31m7.9[0m[31m [0m[1;31m([0m[1;31m0.6[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m. ENALAPRIL [0m
[31mMALEATE: adverse_reactions: [0m[1;31m6[0m[31m Headache [0m[1;31m1.8[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0.9[0m[31m Vertigo [0m[1;31m1.6[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m1.2[0m[31m Respiratory Cough [0m[1;31m2.2[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m [0m[1;31m0.6[0m[31m Bronchitis [0m[1;31m1.3[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m [0m[1;31m0.9[0m[31m Dyspnea [0m[1;31m1.3[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0.4[0m[31m Pneumonia [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m [0m[1;31m2.4[0m[31m Skin Rash [0m[1;31m1.3[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m [0m[1;31m2.4[0m[31m [0m
[31mUrogenital Urinary Tract Infection [0m[1;31m1.3[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m [0m[1;31m2.4[0m[31m Other serious clinical adverse experiences occurring since the drug was marketed or adverse experiences occurring in [0m[1;31m0.5[0m[31m to [0m[1;31m1[0m[31m percent of patients with [0m
[31mhypertension or heart failure in clinical trials are listed below and, within each category, are in order of decreasing severity. Body As A Whole Anaphylactoid reactions [0m[1;31m([0m[31msee WARNINGS, Anaphylactoid [0m
[31mand Possibly Related Reactions [0m[1;31m)[0m[31m. ENALAPRIL MALEATE: adverse_reactions: Cardiovascular Cardiac arrest; myocardial infarction or cerebrovascular accident, possibly secondary to excessive hypotension in[0m
[31mhigh risk patients [0m[1;31m([0m[31msee WARNINGS, Hypotension [0m[1;31m)[0m[31m; pulmonary embolism and infarction; pulmonary edema; rhythm disturbances including atrial tachycardia and bradycardia; atrial fibrillation; palpitation,[0m
[31mRaynaud's phenomenon. Digestive Ileus, pancreatitis, hepatic failure, hepatitis [0m[1;31m([0m[31mhepatocellular [0m[31m or cholestatic jaundice[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee WARNINGS, Hepatic Failure [0m[1;31m)[0m[31m, melena, anorexia, dyspepsia, constipation, [0m
[31mglossitis, stomatitis, dry mouth. Hematologic Rare cases of neutropenia, thrombocytopenia and bone marrow depression. Musculoskeletal Muscle cramps. ENALAPRIL MALEATE: adverse_reactions: [0m
[31mNervous/Psychiatric Depression, confusion, ataxia, somnolence, insomnia, nervousness, peripheral neuropathy [0m[1;31m([0m[31me.g., paresthesia, dysesthesia[0m[1;31m)[0m[31m, dream abnormality. Respiratory Bronchospasm, rhinorrhea, [0m
[31msore throat and hoarseness, asthma, upper respiratory infection, pulmonary infiltrates, eosinophilic pneumonitis. Skin Exfoliative dermatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, [0m
[31mpemphigus, herpes zoster, erythema multiforme, urticaria, pruritus, alopecia, flushing, diaphoresis, photosensitivity. Special Senses Blurred vision, taste alteration, anosmia, tinnitus, [0m
[31mconjunctivitis, dry eyes, tearing. ENALAPRIL MALEATE: adverse_reactions: Urogenital Renal failure, oliguria, renal dysfunction [0m[1;31m([0m[31msee PRECAUTIONS and DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m, flank pain, [0m
[31mgynecomastia, impotence. Miscellaneous A symptom complex has been reported which may include some or all of the following: a positive ANA, an elevated erythrocyte sedimentation rate, [0m
[31marthralgia/arthritis, myalgia/myositis, fever, serositis, vasculitis, leukocytosis, eosinophilia, photosensitivity, rash and other dermatologic manifestations. Angioedema Angioedema has been reported [0m
[31min patients receiving enalapril maleate, with an incidence higher in black than in non-black patients. Angioedema associated with laryngeal edema may be fatal.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: adverse_reactions_table: [0m[1;31m1[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> Fatigue<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1.8[0m[31m [0m
[1;31m([0m[1;31m0[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1.8[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> Abdominal Pain<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1.6[0m[31m [0m
[1;31m([0m[1;31m0.4[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m2.1[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> Asthenia<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1.6[0m[31m [0m
[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m0[0m[31m. ENALAPRIL MALEATE: adverse_reactions_table: [0m[1;31m3[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Cardiovascular<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m/[0m[31m><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m/[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> Hypotension<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m6.7[0m[31m [0m[1;31m([0m[1;31m1.9[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m0.6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> Orthostatic Hypotension<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1.6[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m0[0m[31m. ENALAPRIL MALEATE: adverse_reactions_table: [0m[1;31m3[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> Angina Pectoris<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1.5[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1.8[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> Myocardial Infarction<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1.2[0m[31m [0m[1;31m([0m[1;31m0.3[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1[0m[31m. ENALAPRIL MALEATE: adverse_reactions_table: [0m[1;31m8[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Digestive<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m/[0m[31m><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m/[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> Diarrhea<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m2.1[0m[31m [0m
[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1.2[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> Nausea<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1.3[0m[31m [0m
[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m0.6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> Vomiting<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1[0m[31m. [0m
[31mENALAPRIL MALEATE: adverse_reactions_table: [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m0.9[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Nervous/Psychiatric<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m/[0m[31m><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m/[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> Dizziness<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m7.9[0m[31m [0m[1;31m([0m[1;31m0.6[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m0.6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> Headache<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1.8[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m0[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: adverse_reactions: If angioedema of the face, extremities, lips, tongue, glottis and/or larynx occurs, treatment with enalapril maleate should be discontinued and [0m
[31mappropriate therapy instituted immediately [0m[1;31m([0m[31msee WARNINGS, Head and Neck Angioedema [0m[1;31m)[0m[31m. Hypotension In the hypertensive patients, hypotension occurred in [0m[1;31m0.9[0m[31m percent and syncope occurred in [0m[1;31m0.5[0m[31m percent [0m
[31mof patients following the initial dose or during extended therapy. Hypotension or syncope was a cause for discontinuation of therapy in [0m[1;31m0.1[0m[31m percent of hypertensive patients. In heart failure patients,[0m
[31mhypotension occurred in [0m[1;31m6.7[0m[31m percent and syncope occurred in [0m[1;31m2.2[0m[31m percent of patients. Hypotension or syncope was a cause for discontinuation of therapy in [0m[1;31m1.9[0m[31m percent of patients with heart failure [0m
[1;31m([0m[31msee WARNINGS, Hypotension [0m[1;31m)[0m[31m. Cough See PRECAUTIONS, Cough . ENALAPRIL MALEATE: adverse_reactions: Pediatric Patients The adverse experience profile for pediatric patients appears to be similar to [0m
[31mthat seen in adult patients. Clinical Laboratory Test Findings Serum Electrolytes Hyperkalemia [0m[1;31m([0m[31msee PRECAUTIONS, Hyperkalemia [0m[1;31m)[0m[31m, hyponatremia. Creatinine, Blood Urea Nitrogen In controlled clinical [0m
[31mtrials minor increases in blood urea nitrogen and serum creatinine, reversible upon discontinuation of therapy, were observed in about [0m[1;31m0.2[0m[31m percent of patients with essential hypertension treated with [0m
[31menalapril maleate alone. Increases are more likely to occur in patients receiving concomitant diuretics or in patients with renal artery stenosis [0m[1;31m([0m[31msee PRECAUTIONS, Impaired Renal Function [0m[1;31m)[0m[31m. ENALAPRIL[0m
[31mMALEATE: adverse_reactions: In patients with heart failure who were also receiving diuretics with or without digitalis, increases in blood urea nitrogen or serum creatinine, usually reversible upon [0m
[31mdiscontinuation of enalapril maleate and/or other concomitant diuretic therapy, were observed in about [0m[1;31m11[0m[31m percent of patients. Increases in blood urea nitrogen or creatinine were a cause for [0m
[31mdiscontinuation in [0m[1;31m1.2[0m[31m percent of patients. Hematology Small decreases in hemoglobin and hematocrit [0m[1;31m([0m[31mmean decreases of approximately [0m[1;31m0.3[0m[31m g percent and [0m[1;31m1[0m[31m vol percent, respectively[0m[1;31m)[0m[31m occur frequently in [0m
[31meither hypertension or congestive heart failure patients treated with enalapril maleate but are rarely of clinical importance unless another cause of anemia coexists. In clinical trials, less than [0m[1;31m0.1[0m
[31mpercent of patients discontinued therapy due to anemia. ENALAPRIL MALEATE: adverse_reactions: Hemolytic anemia, including cases of hemolysis in patients with G6PD deficiency, has been reported; a [0m
[31mcausal relationship to enalapril cannot be excluded. Liver Function Tests Elevations of liver enzymes and/or serum bilirubin have occurred [0m[1;31m([0m[31msee WARNINGS, Hepatic Failure [0m[1;31m)[0m[31m. To report SUSPECTED ADVERSE[0m
[31mREACTIONS, contact Northstar Rx LLC at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-[0m[1;31m206[0m[31m-[0m[1;31m7821[0m[31m or FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www.fda.gov/medwatch.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: warnings: Intestinal Angioedema Intestinal angioedema has been reported in patients treated with ACE inhibitors. These patients presented with abdominal pain [0m[1;31m([0m[31mwith or [0m
[31mwithout nausea or vomiting[0m[1;31m)[0m[31m; in some cases there was no prior history of facial angioedema and C1 esterase levels were normal. The angioedema was diagnosed by procedures including abdominal CT scan or[0m
[31multrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential diagnosis of patients on ACE inhibitors presenting with [0m
[31mabdominal pain. Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor [0m[1;31m([0m[31msee INDICATIONS AND USAGE and [0m
[31mCONTRAINDICATIONS [0m[1;31m)[0m[31m. Anaphylactoid Reactions During Desensitization Two patients undergoing desensitizing treatment with hymenoptera venom while receiving ACE inhibitors sustained life-threatening [0m
[31manaphylactoid reactions. ENALAPRIL MALEATE: warnings: In the same patients, these reactions were avoided when ACE inhibitors were temporarily withheld, but they reappeared upon inadvertent [0m
[31mrechallenge. Anaphylactoid Reactions During Membrane Exposure Anaphylactoid reactions have been reported in patients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. [0m
[31mAnaphylactoid reactions have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption. Hypotension Excessive hypotension is rare in uncomplicated [0m
[31mhypertensive patients treated with enalapril maleate alone. Patients with heart failure given enalapril maleate commonly have some reduction in blood pressure, especially with the first dose, but [0m
[31mdiscontinuation of therapy for continuing symptomatic hypotension usually is not necessary when dosing instructions are followed; caution should be observed when initiating therapy [0m[1;31m([0m[31msee DOSAGE AND [0m
[31mADMINISTRATION [0m[1;31m)[0m[31m. ENALAPRIL MALEATE: warnings: Patients at risk for excessive hypotension, sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or [0m
[31mdeath, include those with the following conditions or characteristics: heart failure, hyponatremia, high-dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, [0m
[31mor severe volume and/or salt depletion of any etiology. It may be advisable to eliminate the diuretic [0m[1;31m([0m[31mexcept in patients with heart failure[0m[1;31m)[0m[31m, reduce the diuretic dose or increase salt intake [0m
[31mcautiously before initiating therapy with enalapril maleate in patients at risk for excessive hypotension who are able to tolerate such adjustments [0m[1;31m([0m[31msee PRECAUTIONS, Drug Interactions and ADVERSE [0m
[31mREACTIONS [0m[1;31m)[0m[31m. ENALAPRIL MALEATE: warnings: In patients at risk for excessive hypotension, therapy should be started under very close medical supervision and such patients should be followed closely for[0m
[31mthe first two weeks of treatment and whenever the dose of enalapril and/or diuretic is increased. Similar considerations may apply to patients with ischemic heart or cerebrovascular disease, in whom [0m
[31man excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident. If excessive hypotension occurs, the patient should be placed in the supine position and, if [0m
[31mnecessary, receive an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further doses of enalapril maleate, which usually can be given without [0m
[31mdifficulty once the blood pressure has stabilized. If symptomatic hypotension develops, a dose reduction or discontinuation of enalapril maleate or concomitant diuretic may be necessary. ENALAPRIL [0m
[31mMALEATE: warnings: Neutropenia/Agranulocytosis Another angiotensin-converting enzyme inhibitor, captopril, has been shown to cause agranulocytosis and bone marrow depression, rarely in uncomplicated [0m
[31mpatients but more frequently in patients with renal impairment, especially if they also have a collagen vascular disease. Available data from clinical trials of enalapril are insufficient to show that[0m
[31menalapril does not cause agranulocytosis at similar rates. Marketing experience has revealed cases of neutropenia or agranulocytosis in which a causal relationship to enalapril cannot be excluded. [0m
[31mPeriodic monitoring of white blood cell counts in patients with collagen vascular disease and renal disease should be considered. Hepatic Failure Rarely, ACE inhibitors have been associated with a [0m
[31msyndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis, and [0m[1;31m([0m[31msometimes[0m[1;31m)[0m[31m death. The mechanism of this syndrome is not understood.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: openfda: product_ndc         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: openfda: brand_name         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: openfda: package_ndc         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: pharmacodynamics: Pharmacodynamics and Clinical Effects Hypertension Administration of enalapril maleate to patients with hypertension of severity ranging from mild to [0m
[31msevere results in a reduction of both supine and standing blood pressure usually with no orthostatic component. Symptomatic postural hypotension is therefore infrequent, although it might be [0m
[31manticipated in volume-depleted patients [0m[1;31m([0m[31msee WARNINGS, Hypotension [0m[1;31m)[0m[31m. In most patients studied, after oral administration of a single dose of enalapril, onset of antihypertensive activity was seen at [0m
[31mone hour with peak reduction of blood pressure achieved by four to six hours. At recommended doses, antihypertensive effects have been maintained for at least [0m[1;31m24[0m[31m hours. In some patients the effects [0m
[31mmay diminish toward the end of the dosing interval [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION , Hypertension [0m[1;31m)[0m[31m. In some patients achievement of optimal blood pressure reduction may require several weeks of [0m
[31mtherapy. ENALAPRIL MALEATE: pharmacodynamics: The antihypertensive effects of enalapril maleate have continued during long-term therapy. Abrupt withdrawal of enalapril maleate has not been associated [0m
[31mwith a rapid increase in blood pressure. In hemodynamic studies in patients with essential hypertension, blood pressure reduction was accompanied by a reduction in peripheral arterial resistance with [0m
[31man increase in cardiac output and little or no change in heart rate. Following administration of enalapril maleate, there is an increase in renal blood flow; glomerular filtration rate is usually [0m
[31munchanged. The effects appear to be similar in patients with renovascular hypertension. When given together with thiazide-type diuretics, the blood pressure lowering effects of enalapril maleate are [0m
[31mapproximately additive. In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving enalapril maleate. ENALAPRIL MALEATE: pharmacodynamics: In this [0m
[31mstudy there was no evidence of a blunting of the antihypertensive action of enalapril maleate [0m[1;31m([0m[31msee PRECAUTIONS, Drug Interactions [0m[1;31m)[0m[31m. Heart Failure In trials in patients treated with digitalis and [0m
[31mdiuretics, treatment with enalapril resulted in decreased systemic vascular resistance, blood pressure, pulmonary capillary wedge pressure and heart size, and increased cardiac output and exercise [0m
[31mtolerance. Heart rate was unchanged or slightly reduced, and mean ejection fraction was unchanged or increased. There was a beneficial effect on severity of heart failure as measured by the New York [0m
[31mHeart Association [0m[1;31m([0m[31mNYHA[0m[1;31m)[0m[31m classification and on symptoms of dyspnea and fatigue. Hemodynamic effects were observed after the first dose and appeared to be maintained in uncontrolled studies lasting as [0m
[31mlong as four months. Effects on exercise tolerance, heart size, and severity and symptoms of heart failure were observed in placebo-controlled studies lasting from eight weeks to over one year. [0m
[31mENALAPRIL MALEATE: pharmacodynamics: Heart Failure, Mortality Trials In a multicenter, placebo-controlled clinical trial, [0m[1;31m2[0m[31m,[0m[1;31m569[0m[31m patients with all degrees of symptomatic heart failure and ejection [0m
[31mfraction â‰¤[0m[1;31m35[0m[31m percent were randomized to placebo or enalapril and followed for up to [0m[1;31m55[0m[31m months [0m[1;31m([0m[31mSOLVD-Treatment[0m[1;31m)[0m[31m. Use of enalapril was associated with an [0m[1;31m11[0m[31m percent reduction in all-cause mortality and[0m
[31ma [0m[1;31m30[0m[31m percent reduction in hospitalization for heart failure. Diseases that excluded patients from enrollment in the study included severe stable angina [0m[1;31m([0m[31m>[0m[1;31m2[0m[31m attacks/day[0m[1;31m)[0m[31m, hemodynamically significant [0m
[31mvalvular or outflow tract obstruction, renal failure [0m[1;31m([0m[31mcreatinine >[0m[1;31m2.5[0m[31m mg/dL[0m[1;31m)[0m[31m, cerebrovascular disease [0m[1;31m([0m[31me.g., significant carotid artery disease[0m[1;31m)[0m[31m, advanced pulmonary disease, malignancies, active [0m
[31mmyocarditis and constrictive pericarditis. The mortality benefit associated with enalapril does not appear to depend upon digitalis being present.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: indications_and_usage: INDICATIONS AND USAGE Hypertension Enalapril maleate tablets, USP are indicated for the treatment of hypertension. Enalapril maleate tablets, USP are[0m
[31meffective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately [0m
[31madditive. Heart Failure Enalapril maleate tablets, USP are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients [0m
[31menalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of [0m
[31msurvival trials[0m[1;31m)[0m[31m. ENALAPRIL MALEATE: indications_and_usage: Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction [0m[1;31m([0m[31mejection fraction [0m
[31mâ‰¤[0m[1;31m35[0m[31m percent[0m[1;31m)[0m[31m, enalapril maleate tablets, USP decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY, Heart[0m
[31mFailure, Mortality Trials for details and limitations of survival trials[0m[1;31m)[0m[31m. In using enalapril maleate, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, [0m
[31mcaptopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not [0m
[31mhave a similar risk [0m[1;31m([0m[31msee WARNINGS , Neutropenia/Agranulocytosis [0m[1;31m)[0m[31m. ENALAPRIL MALEATE: indications_and_usage: In considering use of enalapril maleate, it should be noted that in controlled clinical [0m
[31mtrials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been [0m
[31mreported to have a higher incidence of angioedema compared to non-blacks [0m[1;31m([0m[31msee WARNINGS, Head and Neck Angioedema [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: clinical_pharmacology: In most patients studied, after oral administration of a single dose of enalapril, onset of antihypertensive activity was seen at one hour with peak [0m
[31mreduction of blood pressure achieved by four to six hours. At recommended doses, antihypertensive effects have been maintained for at least [0m[1;31m24[0m[31m hours. In some patients the effects may diminish toward [0m
[31mthe end of the dosing interval [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION , Hypertension [0m[1;31m)[0m[31m. In some patients achievement of optimal blood pressure reduction may require several weeks of therapy. The [0m
[31mantihypertensive effects of enalapril maleate have continued during long-term therapy. Abrupt withdrawal of enalapril maleate has not been associated with a rapid increase in blood pressure. In [0m
[31mhemodynamic studies in patients with essential hypertension, blood pressure reduction was accompanied by a reduction in peripheral arterial resistance with an increase in cardiac output and little or [0m
[31mno change in heart rate. ENALAPRIL MALEATE: clinical_pharmacology: Following administration of enalapril maleate, there is an increase in renal blood flow; glomerular filtration rate is usually [0m
[31munchanged. The effects appear to be similar in patients with renovascular hypertension. When given together with thiazide-type diuretics, the blood pressure lowering effects of enalapril maleate are [0m
[31mapproximately additive. In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving enalapril maleate. In this study there was no evidence of a [0m
[31mblunting of the antihypertensive action of enalapril maleate [0m[1;31m([0m[31msee PRECAUTIONS, Drug Interactions [0m[1;31m)[0m[31m. Heart Failure In trials in patients treated with digitalis and diuretics, treatment with enalapril [0m
[31mresulted in decreased systemic vascular resistance, blood pressure, pulmonary capillary wedge pressure and heart size, and increased cardiac output and exercise tolerance. ENALAPRIL MALEATE: [0m
[31mclinical_pharmacology: Heart rate was unchanged or slightly reduced, and mean ejection fraction was unchanged or increased. There was a beneficial effect on severity of heart failure as measured by [0m
[31mthe New York Heart Association [0m[1;31m([0m[31mNYHA[0m[1;31m)[0m[31m classification and on symptoms of dyspnea and fatigue. Hemodynamic effects were observed after the first dose and appeared to be maintained in uncontrolled [0m
[31mstudies lasting as long as four months. Effects on exercise tolerance, heart size, and severity and symptoms of heart failure were observed in placebo-controlled studies lasting from eight weeks to [0m
[31mover one year. Heart Failure, Mortality Trials In a multicenter, placebo-controlled clinical trial, [0m[1;31m2[0m[31m,[0m[1;31m569[0m[31m patients with all degrees of symptomatic heart failure and ejection fraction â‰¤[0m[1;31m35[0m[31m percent were [0m
[31mrandomized to placebo or enalapril and followed for up to [0m[1;31m55[0m[31m months [0m[1;31m([0m[31mSOLVD-Treatment[0m[1;31m)[0m[31m. Use of enalapril was associated with an [0m[1;31m11[0m[31m percent reduction in all-cause mortality and a [0m[1;31m30[0m[31m percent reduction in[0m
[31mhospitalization for heart failure. ENALAPRIL MALEATE: clinical_pharmacology: Diseases that excluded patients from enrollment in the study included severe stable angina [0m[1;31m([0m[31m>[0m[1;31m2[0m[31m attacks/day[0m[1;31m)[0m[31m, [0m
[31mhemodynamically significant valvular or outflow tract obstruction, renal failure [0m[1;31m([0m[31mcreatinine [0m[1;31m>[0m[1;31m2.5[0m[31m mg/dL[0m[1;31m)[0m[31m, cerebrovascular disease [0m[1;31m([0m[31me.g., significant carotid artery disease[0m[1;31m)[0m[31m, advanced pulmonary [0m
[31mdisease, malignancies, active myocarditis and constrictive pericarditis. The mortality benefit associated with enalapril does not appear to depend upon digitalis being present. A second multicenter [0m
[31mtrial used the SOLVD protocol for study of asymptomatic or minimally symptomatic patients. SOLVD-Prevention patients, who had left ventricular ejection fraction â‰¤[0m[1;31m35[0m[31m percent and no history of [0m
[31msymptomatic heart failure, were randomized to placebo [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m2[0m[31m,[0m[1;31m117[0m[1;31m)[0m[31m or enalapril [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m2[0m[31m,[0m[1;31m111[0m[1;31m)[0m[31m and followed for up to [0m[1;31m5[0m[31m years. ENALAPRIL MALEATE: clinical_pharmacology: The majority of patients in the [0m
[31mSOLVD-Prevention trial had a history of ischemic heart disease. A history of myocardial infarction was present in [0m[1;31m80[0m[31m percent of patients, current angina pectoris in [0m[1;31m34[0m[31m percent, and a history of [0m
[31mhypertension in [0m[1;31m37[0m[31m percent. No statistically significant mortality effect was demonstrated in this population. Enalapril-treated subjects had [0m[1;31m32[0m[31m percent fewer first hospitalizations for heart failure,[0m
[31mand [0m[1;31m32[0m[31m percent fewer total heart failure hospitalizations. Compared to placebo, [0m[1;31m32[0m[31m percent fewer patients receiving enalapril developed symptoms of overt heart failure. Hospitalizations for [0m
[31mcardiovascular reasons were also reduced. There was an insignificant reduction in hospitalizations for any cause in the enalapril treatment group [0m[1;31m([0m[31mfor enalapril vs. placebo, respectively, [0m[1;31m1166[0m[31m vs. [0m
[1;31m1201[0m[31m first hospitalizations, [0m[1;31m2649[0m[31m vs. [0m[1;31m2840[0m[31m total hospitalizations[0m[1;31m)[0m[31m, although the study was not powered to look for such an effect.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The available information from the ENALAPRIL MALEATE label does not specifically mention an increase or decrease in the risk of bleeding as an adverse reaction. However, it does list rare [0m
[32mcases of thrombocytopenia, which is a condition that can increase the risk of bleeding due to a reduced number of platelets in the blood.[0m

[32mSOURCE: ENALAPRIL MALEATE label[0m
[32mEXTRACT_START_END: Hematologic Rare cases of neutropenia, thrombocytopenia[0m[32m...[0m
*[1m([0morchestrator-bleeding-ENALAPRIL MALEATE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The available information from the ENALAPRIL MALEATE label does[0m
[34mnot specifically mention an increase or decrease in the risk of bleeding as an adverse reaction. However, it does list rare cases of thrombocytopenia, which is a condition that can increase the risk [0m
[34mof bleeding due to a reduced number of platelets in the blood.[0m

[34mSOURCE: ENALAPRIL MALEATE label[0m
[34mEXTRACT_START_END: Hematologic Rare cases of neutropenia, thrombocytopenia[0m[34m...[0m
 [1m([0morchestrator-bleeding-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-bleeding-ENALAPRIL MALEATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ENALAPRIL MALEATE increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether ENALAPRIL MALEATE increases or decreases the risk of bleeding."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the ENALAPRIL MALEATE label does not specifically mention an increase or decrease in the risk of bleeding as an adverse reaction. However, it does list rare cases of [0m
[32mthrombocytopenia, which is a condition that can increase the risk of bleeding due to a reduced number of platelets in the blood."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"ENALAPRIL MALEATE does not specifically list an increase or decrease in the risk of bleeding as a known side effect according to the label. However, it does mention rare cases of [0m
[32mthrombocytopenia, which could potentially increase the risk of bleeding. The degree of risk associated with ENALAPRIL MALEATE in terms of bleeding is not clearly defined, but the occurrence of [0m
[32mthrombocytopenia is considered rare."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-ENALAPRIL MALEATE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-bleeding-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-ENALAPRIL MALEATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-bleeding-ENALAPRIL MALEATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ENALAPRIL MALEATE increase or decrease the risk of bleeding?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether ENALAPRIL MALEATE increases or decreases the risk of bleeding."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the ENALAPRIL MALEATE label does not specifically mention an increase or decrease in the risk of bleeding as an adverse reaction. However, it does list rare cases of [0m
[34mthrombocytopenia, which is a condition that can increase the risk of bleeding due to a reduced number of platelets in the blood."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"ENALAPRIL MALEATE does not specifically list an increase or decrease in the risk of bleeding as a known side effect according to the label. However, it does mention rare cases of [0m
[34mthrombocytopenia, which could potentially increase the risk of bleeding. The degree of risk associated with ENALAPRIL MALEATE in terms of bleeding is not clearly defined, but the occurrence of [0m
[34mthrombocytopenia is considered rare."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ENALAPRIL MALEATE increase or decrease the risk of bleeding?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether ENALAPRIL MALEATE increases or decreases the risk of bleeding.[0m
[1;31m2[0m[31m. FDAHandler responded that the ENALAPRIL MALEATE label does not specifically mention an increase or decrease in the risk of bleeding as an adverse reaction. However, it does list rare cases of [0m
[31mthrombocytopenia, which is a condition that can increase the risk of bleeding due to a reduced number of platelets in the blood.[0m
[31m        -----[0m
[31m        Final answer: ENALAPRIL MALEATE does not specifically list an increase or decrease in the risk of bleeding as a known side effect according to the label. However, it does mention rare cases of[0m
[31mthrombocytopenia, which could potentially increase the risk of bleeding. The degree of risk associated with ENALAPRIL MALEATE in terms of bleeding is not clearly defined, but the occurrence of [0m
[31mthrombocytopenia is considered rare.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-bleeding-ENALAPRIL MALEATE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-bleeding-ENALAPRIL MALEATE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-bleeding-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-bleeding-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-bleeding-ENALAPRIL MALEATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe final answer to the question [0m[32m"Does ENALAPRIL MALEATE increase or decrease the risk of bleeding?"[0m[32m is as follows:[0m

[32mENALAPRIL MALEATE does not specifically list an increase or decrease in the risk of bleeding as a known side effect according to the label. However, it does mention rare cases of thrombocytopenia, [0m
[32mwhich could potentially increase the risk of bleeding. The degree of risk associated with ENALAPRIL MALEATE in terms of bleeding is not clearly defined, but the occurrence of thrombocytopenia is [0m
[32mconsidered rare.[0m
